TRUSTEES OF BOSTON UNIVERSITY

• THE CHARLES STARK DRAPER LABORATORY, INC.

  UEI GTJHZE4M7YK1

  $5M

  Subcontractor to this prime · 1 sub-award · latest Dec 23, 2024

  • Office of Assistant Secretary for Preparedness and Response
  • “COMPANY WILL PROVIDE DRAPER WITH TECHNICAL SUPPORT FOR PROGRAM.”
• TRIAD NATIONAL SECURITY, LLC

  UEI X7WUS5LRBQU3

  $359K

  Subcontractor to this prime · 1 sub-award · latest Mar 25, 2026

  • Department of Energy
  • “BOSTON UNIVERSITY-STAND ALONE-ITEM LEVEL-R AND D”
• HONEYWELL FEDERAL MANUFACTURING & TECHNOLOGIES, LLC

  UEI DMEGBYTVBQS5

  $165.9K

  Subcontractor to this prime · 2 sub-awards · latest Jan 5, 2026

  • Department of Energy
  • “R&D”
  • “RESEARCH AND DEVELOPMENT”
• REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE

  UEI GS3YEVSS12N6

  $49.5K

  Subcontractor to this prime · 1 sub-award · latest Apr 9, 2026

  • National Aeronautics and Space Administration
  • “THE CARRUTHERS GEOCORONA OBSERVATORY IS A SMALL SATELLITE MISSION TO STUDY THE EXTENDED HYDROGEN ATMOSPHERE OF THE EARTH, ALSO KNOWN AS THE GEOCORONA. THIS IS A SIMPLE INSTRUMENT, WITH TWO IMAGING CHANNELS TO RECORD THE HYDROGEN LYMAN-ALPHA EMISSION FROM THE GEOCORONA THAT RESULTS FROM SCATTERED SOLAR LIGHT. THE INSTRUMENT WORKS AT VACUUM ULTRAVIOLET WAVELENGTHS, AND THUS HAS TO BE ABOVE THE ATMOSPHERE (AND ALSO OUTSIDE THE GEOCORONA) TO MAKE THESE MEASUREMENTS. THE PROGRAM IS SMALL, SELF CONTAINED SPACECRAFT THAT CAN BE LAUNCHED WITH THE LARGE IMAP MISSION AND THEN DROPPED OFF NEAR THE SUN-EARTH L1 POINT. FROM THERE CARRUTHERS WILL TAKE IMAGES LOOKING BACK AT THE EARTH. THE SCIENTIFIC INSTRUMENT PACKAGE IS PRODUCED AT THE SPACE SCIENCES LAB. AT THE UNIV. OF CALIFORNIA, BERKELEY, AND THE SPACECRAFT IS PRODUCED AT BRITISH AEROSPACE (FORMERLY BALL AEROSPACE) IN BOULDER CO. PROF. JOHN T. CLARKE OF BOSTON UNIVERSITY IS THE DEPUTY PRINCIPAL INVESTIGATOR ON THE CARRUTHERS PROJECT, FOR WHICH THE PRINCIPAL INVESTIGATOR (PI) IS PROF. LARA WALDROP AT THE UNIV. OF ILLINOIS. CLARKE PARTICIPATES IN THE CARRUTHERS PROJECT, FUNDED BY NASA, AND FULFILLS THE RESPONSIBILITIES LISTED IN THE PROPOSAL TO NASA. THE SPECIFIC TASKS AND SCOPE OF THE ACTIVITIES AT BOSTON UNIVERSITY LED BY PROF. CLARKE AS LOCAL PI.”

• LIMMATECH BIOLOGICS AG

  UEI MWBLS4LKYNP9 · not in the directory yet

  $10M

  Subcontracted by this company · 2 sub-awards · latest Mar 12, 2024

  • Office of Assistant Secretary for Preparedness and Response
  • “STAPHYLOCOCCUS AUREUS (SA), CAUSES SERIOUS DISEASES INCLUDING BLOOD STREAM INFECTION, SEPSIS, ENDOCARDITIS, SURGICAL SITE INFECTIONS (SSI), AND PNEUMONIA. METHICILLIN RESISTANT SA (MRSA) IS CURRENTLY A LEADING CAUSE OF THESE LIFE THREATENING INFECTIONS WITH LIMITED OPTIONS FOR TREATMENT. FOUR VACCINE AND IMMUNOTHERAPEUTIC APPROACHES TARGETING SA SURFACE ANTIGENS HAVE BEEN TESTED IN EFFICACY TRIALS IN HUMANS AND ALL HAVE FAILED. ONE OF THESE VACCINES (V710) CAUSED MULTI-ORGAN FAILURE IN VACCINATED INDIVIDUALS WHO WERE INFECTED WITH SA LEADING TO TRIAL TERMINATION BY FDA. STUDIES IN ANIMALS HAVE ALSO SHOWN THAT VACCINES TARGETING SURFACE ANTIGENS INCREASE THE RISK OF DEATH FROM SA INFECTION. THIS PROJECT SEEKS TO DEVELOP A NOVEL, ENTIRELY TOXOID BASED VACCINE (LTB-SA7) FOR PREVENTION OF MRSA INFECTIONS. LTB-SA7 CONSISTS OF FIVE COMPONENTS REPRESENTING TOXOIDS FOR SIX SA TOXINS. DUE TO CROSS REACTIVITY, THESE TOXOIDS ELICIT PROTECTIVE RESPONSES TO 12-15 SA TOXINS. EFFICACY OF THE LTB-SA7 COMPONENTS HAS BEEN SHOWN IN VARIOUS MOUSE AND RABBIT MODELS OF INFECTION. THIS IS THE FIRST ENTIRELY NON-SURFACE ANTIGEN BASED VACCINE FOR SA DISEASE. THE STUDIES COMPLETED UNDER CARB-X SUPPORT PRECLINICAL ACTIVITIES, GMP MANUFACTURING AND IND ACTIVATION, AND ENTER INTO A PHASE I CLINICAL TRIAL. FOLLOWING THIS FUNDING PERIOD, LIMMATECH BIOLOGICS AG INTENDS TO TEST THE VACCINE IN PHASE II AND PHASE III CLINICAL TRIALS FOR PREVENTION OF SSTI IN RECURRENT SA SKIN INFECTIONS AND LATER IN SSI IN ELECTIVE SURGERIES. A TEAM OF EXPERIENCED SCIENTISTS AND PROGRAM MANAGERS AT LIMMATECH BIOLOGICS AG WILL LEAD THE PROGRAM. WORLD EXPERTS AND COLLABORATORS IN THE FIELD OF SA WILL COLLABORATE WITH LIMMATECH BIOLOGICS AG ON THIS PROJECT.”
  • “THE CONCURRENT RISE OF ANTIMICROBIAL RESISTANCE AND INCIDENCE OF SEXUALLY TRANSMITTED INFECTIONS IS A WORRYING COMBINATION. IN THE PAST DECADE, CASES OF GONORRHEA HAVE MORE THAN DOUBLED IN MANY COUNTRIES – IN THE US THERE ARE AN ESTIMATED 1.6 MILLION NEW INFECTIONS EACH YEAR, HALF OF WHICH ARE ANTIBIOTIC RESISTANT. OVER THE PAST 80 YEARS, NEISSERIA GONORRHOEAE, THE CAUSATIVE AGENT OF GONORRHEA, HAS STEADILY DEVELOPED RESISTANCE TO ALL ANTIMICROBIAL TREATMENTS. ALREADY TODAY, ONLY ONE RECOMMENDED TREATMENT OPTION REMAINS, AND FAILURES HAVE BEEN OBSERVED IN MULTIPLE COUNTRIES. GONORRHEA WILL CONTINUE TO DEVELOP RESISTANCE TO ANY NEW ANTIMICROBIALS, AND IN JUST A FEW YEARS UNTREATABLE DISEASE COULD BE WIDESPREAD. AN ALTERNATIVE SOLUTION IS URGENTLY NEEDED – A VACCINE. THERE ARE NO KNOWN EXAMPLES OF A PATHOGEN DEVELOPING RESISTANCE TO A VACCINE, AND ONLY LIMITED EXAMPLES OF EVASION BY SEROTYPE REPLACEMENT. BY PREVENTING INFECTIONS AND ILLNESS, ANTIBIOTIC PRESCRIPTIONS ARE REDUCED, AND SO IS DEVELOPMENT OF RESISTANCE. WIDESPREAD USE OF PNEUMOCOCCAL VACCINES HAS EVEN BEEN SHOWN TO SIGNIFICANTLY REDUCE CIRCULATING LEVELS OF RESISTANT BACTERIA. LIMMATECH BIOLOGICS AG IS DEVELOPING A VACCINE IS BASED ON A COMBINATION OF NOVEL ANTIGENS DELIVERED IN A NOVEL PRODUCTION PLATFORM. IMMUNE EVASION BY N. GONORRHOEAE MEANS THAT NATURAL INFECTION WITH THE PATHOGEN DOES NOT RESULT IN PROTECTIVE IMMUNITY, AND MANY GONOCOCCAL SURFACE ANTIGENS ARE HIGHLY VARIABLE IN STRUCTURE OR EXPRESSION, MAKING THEM POOR TARGETS FOR VACCINATION. OUR VACCINE IS DESIGNED TO OVERCOME THESE MECHANISMS BY AVOIDING PHASE VARIABLE STRUCTURES AND IMMUNOGENIC SURFACE DECOY ANTIGENS. ALL OUR ANTIGENS ARE HIGHLY CONSERVED BETWEEN STRAINS, INCLUDING RECENT AND RESISTANT CLINICAL ISOLATES, AND THIS, TOGETHER WITH THE MULTIVALENT DESIGN OF THE VACCINE MEANS COVERAGE IS EXPECTED TO BE 100%. ALL OUR ANTIGENS ARE HIGHLY IMMUNOGENIC IN PRECLINICAL STUDIES. THEY HAVE BEEN EXTENSIVELY VALIDATED USING A SET OF COMPLEMENTAR”
• BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL

  UEI UA43HWRNXFS3 · not in the directory yet

  $9.1M

  Subcontracted by this company · 1 sub-award · latest Apr 4, 2024

  • Office of Assistant Secretary for Preparedness and Response
  • “INFECTIONS CAUSED BY MULTIDRUG-RESISTANT BACTERIA HAVE BECOME ONE OF THE MOST IMPORTANT THREATS TO GLOBAL HEALTH, RESULTING IN AN ESTIMATED 1.27 MILLION GLOBAL DEATHS IN 2019. GRAM-NEGATIVE BACTERIA ARE OF PARTICULAR CONCERN, BECAUSE OF THEIR INTRINSIC RESISTANCE, RAPID ACQUISITION AND SPREAD OF NEW RESISTANCE, AND THE PAUCITY OF NOVEL ANTIBIOTIC DEVELOPMENT TARGETING THESE BACTERIA IN THE LAST DECADES. THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE WORLD HEALTH ORGANIZATION IDENTIFIED CARBAPENEM-RESISTANT ENTEROBACTERIACEAE AS HIGH PRIORITY PATHOGENS FOR WHICH NEW AND EFFECTIVE ANTIBIOTIC TREATMENTS ARE URGENTLY NEEDED. BAL2420 (ALSO NAMED BAL0302420) IS A NOVEL ANTIBACTERIAL CANDIDATE FOR DEVELOPMENT AS INTRAVENOUS (IV) TREATMENT FOR SEVERE INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA. THE COMPOUND IS A 16-MER CYCLIC PEPTIDE WITH A DISULFIDE BRIDGE AND AN INHIBITOR OF THE LIPOPOLYSACCHARIDE TRANSPORT PROTEIN A (LPTA), WHICH IS A NOVEL TARGET/MODE OF ACTION CURRENTLY NOT EXPLOITED BY ANY ANTIBIOTIC CURRENTLY AVAILABLE FOR CLINICAL USE. BAL2420 IS TO BE DEVELOPED AS A SAFE AND EFFECTIVE NOVEL TREATMENT OPTION FOR SERIOUS BACTERIAL INFECTIONS, INCLUDING BLOODSTREAM INFECTIONS ASSOCIATED WITH PNEUMONIA (HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA [HABP] / VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA [VABP]), COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAIS), AND COMPLICATED URINARY TRACT INFECTIONS (CUTIS), AND FOR CIAIS, CUTIS, AND HABP/VABP. IF SUCCESSFULLY DEVELOPED THE PROGRAM WILL PROVIDE A NOVEL CLASS OF ANTIBIOTICS TO TREAT LIFE-THREATENING INFECTIONS CAUSED BY DIFFICULT-TO-TREAT GRAM-NEGATIVE BACTERIA SUCH AS CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) ADDRESSING A HIGH UNMET MEDICAL NEED. BAL2420 SHOWS POTENT, BACTERICIDAL ANTIMICROBIAL ACTIVITY AGAINST ENTEROBACTERIACEAE. ENTEROBACTERIACEAE ARE A FAMILY OF IMPORTANT PATHOGENS CAUSING INFECTIONS IN HUMANS AND INCLUDE BACTERIA SUCH AS ESCHERICHIA COLI OR KLEBSIELLA PNEUMONIAE. BAL2420 IS ALSO ACTIVE AGAINST ANTIB”
• VISBY MEDICAL, INC.

  UEI LWNQZECSVHY1

  $2.4M

  Subcontracted by this company · 1 sub-award · latest Dec 7, 2023

  • Office of Assistant Secretary for Preparedness and Response
  • “VISBY MEDICAL IS THE MAKER OF AN INNOVATIVE INSTRUMENT-FREE, SINGLE USE PCR PLATFORM FOR THE DETECTION OF INFECTIOUS DISEASES. THEIR SEXUAL HEALTH TEST DETECTS CHLAMYDIA, GONORRHEA, AND TRICHOMONAS WITH ~97% ACCURACY IN LESS THAN 30 MINUTES. THIS TEST IS FDA AUTHORIZED FOR OVER THE COUNTER (OTC) USE WITHOUT THE NEED FOR A PRESCRIPTION. CARB-X FUNDING WILL ALLOW VISBY TO ADD THE DETECTION OF ANTIBIOTIC RESISTANCE TO THE SEXUAL HEALTH TEST, BY DEVELOPING OUR ASSAY FOR THE DETECTION OF A MUTATION IN THE GYRA GENE OF N. GONORRHOEAE THAT CONFERS RESISTANCE TO CIPROFLOXACIN. THE CDC LISTS ANTIBIOTIC RESISTANCE IN N. GONORRHOEAE AS ONE OF THE TOP 5 URGENT THREATS. DUE TO LACK OF A DIAGNOSTIC TEST RESULT FOR CIPROFLOXACIN RESISTANCE, CURRENT TREATMENT GUIDELINES RECOMMEND USING ONE OF THE LAST REMAINING ANTIBIOTICS (CEFTRIAXONE) AVAILABLE AGAINST GONORRHEA INFECTIONS. THE NEW VISBY TEST WILL HELP CLINICIANS KNOW WHEN CIPROFLOXACIN CAN BE USED WHICH CAN BE ADMINISTERED ORALLY AND WILL HELP TO CONSERVE OUR LAST LINES OF ANTIBIOTIC DEFENSE ONLY FOR THE CASES THAT REQUIRE IT. BY MAKING A SIMPLE, RAPID DIAGNOSTIC TEST FOR ANTIBIOTIC RESISTANCE, VISBY MEDICAL WILL PROVIDE A MUCH-NEEDED TOOL IN THE FIGHT AGAINST ANTIBIOTIC RESISTANCE.”
• CENTAURI THERAPEUTICS LIMITED

  UEI WATKEAYQXZN3 · not in the directory yet

  $1.8M

  Subcontracted by this company · 1 sub-award · latest Apr 17, 2025

  • Office of Assistant Secretary for Preparedness and Response
  • “CENTAURI IS A PRIVATELY-OWNED BIOTECH COMPANY DEVELOPING NOVEL IMMUNOTHERAPEUTICS TO TREAT LIFE-THREATENING DISEASES. CENTAURI HAS A DEVELOPED AN IMMUNOTHERAPEUTIC PLATFORM (ALPHAMERS) THAT REDIRECTS PRE-EXISTING NATURAL ANTIBODIES TO TARGET SPECIFIC DISEASES WITH APPLICATIONS FOR CANCER AND INFECTIOUS DISEASE. ALPHAMERS ARE PART OF A LARGER FAMILY OF ANTIBODY RECRUITING MOLECULES (ARMS) DESIGNED TO REDIRECT A POTENT PRE-EXISTING IMMUNE RESPONSE AND THEREBY BRING ABOUT AN IMMEDIATE (WITHIN MINUTES) IMMUNOTHERAPEUTIC BENEFIT TO PATIENTS. THE ALPHAMER PLATFORM COMPRISES A TARGETING DOMAIN, THAT BINDS TO SPECIFICALLY TO THE BACTERIA, AN ANTIBODY-RECRUITING EFFECTOR DOMAIN THAT RECRUITS PRE-EXISTING NATURAL ANTI-GAL ANTIBODIES, AND PROPRIETARY LINKER TECHNOLOGY. ANTI-GAL ANTIBODIES ARE THE MOST ABUNDANT ANTIBODIES IN HUMANS, CONSTITUTING ABOUT 1% OF ALL IMMUNOGLOBULINS. THE ALPHAMER IS INTENDED TO RE-DIRECT THESE NATURALLY OCCURRING EFFECTOR ANTIBODIES WHICH ARE ALREADY PRESENT AT HIGH CONCENTRATIONS IN ALL PEOPLE TO TARGET BACTERIA FOR IMMUNE-MEDIATED DESTRUCTION, BY ACTIVATING THE COMPLEMENT CASCADE AND DESTROYING THE PATHOGEN THROUGH DIRECT LYSIS AND OPSONOPHAGOCYTOSIS. OUR LEAD PROGRAM (CTL-ABX01) TARGETS DRUG-SENSITIVE AND MULTI-DRUG RESISTANT (MDR) GRAM-NEGATIVE BACTERIA, INCLUDING CLINICALLY RELEVANT STRAINS OF ENTEROBACTERIACEAE, PSEUDOMONAS AERUGINOSA, AND ACINETOBACTER BAUMANNII. IN ADDITION TO RECRUITING THE IMMUNE SYSTEM, THE TARGETING DOMAIN OF THE ALPHAMER OF THE ABX01 PROGRAM HAS ALSO A DIRECT ANTIBACTERIAL EFFECT IN COMBINATION WITH ITS IMMUNOMODULATOR FUNCTION. AS SUCH, THE ALPHAMER SERVES AS A METHOD TO COMBINE THE POWER OF THE IMMUNE SYSTEM WITH DIRECT ANTIBACTERIAL ACTION IN ONE DRUG. THE AIM OF THIS PILOT PROJECT IS TO BETTER UNDERSTAND THE IMMUNE-MEDIATED TRANSLATION AND EFFICACY OF THE ALPHAMER IN VIVO BY EXECUTING APPROPRIATE DISEASE MODELS IN ORDER TO PREDICT AN EFFICACIOUS DOSE FOR HUMAN. PROJECT SUCCESS WOULD ENABLE US TO SELECT LEAD COM”
• PEPTILOGICS INC

  UEI GQ3MK4JQYEK1

  $1.5M

  Subcontracted by this company · 1 sub-award · latest Dec 6, 2024

  • Office of Assistant Secretary for Preparedness and Response
  • “PEPTILOGICS IS A BIOTECHNOLOGY COMPANY THAT UTILIZES AN INNOVATIVE PLATFORM TO DEVELOP NOVEL PEPTIDE THERAPEUTICS TO ADDRESS UNMET MEDICAL NEEDS. OUR PIPELINE INCLUDES A NOVEL CLASS OF ENGINEERED CATIONIC ANTIBIOTIC PEPTIDES. OUR LEAD CANDIDATE, PLG0206, BASED ON NATURALLY OCCURRING ANTIMICROBIAL PEPTIDES, EXHIBITS BROAD-SPECTRUM ACTIVITY AGAINST CLINICALLY IMPORTANT MDR GRAM-POSITIVE (S. AUREUS, INCLUDING MRSA, AND E. FAECIUM, INCLUDING VRE) AND GRAM-NEGATIVE (P. AERUGINOSA, E. COLI, AND A. BAUMANNII) PATHOGENS. PLG0206 EXHIBITS THE ABILITY TO RAPIDLY INACTIVATE BOTH PLANKTONIC AND BIOFILM PATHOGENS. THIS WITH ITS BROAD-SPECTRUM ACTIVITY MAKE IT AN IDEAL DEVELOPMENT CANDIDATE FOR PREVENTING INVASIVE INFECTIONS. PLG0206 TARGETS AND DISRUPTS THE BACTERIAL MEMBRANE, CAUSING RAPID BACTERIAL DEATH VIA CELLULAR CHEMICAL IMBALANCE. SINCE BACTERIAL MEMBRANES ARE A CONSERVED EVOLUTIONARY TARGET, THIS MOA APPEARS TO LIMIT THE RISK FOR RESISTANCE COMPARED TO OTHER ANTIBIOTICS. WITH RAPID BACTERICIDAL AND ANTI-BIOFILM ACTIVITY ON CONTACT, PLG0206 IS BEING DEVELOPED FOR THE PREVENTION OF TRAUMATIC FRACTURE-RELATED INFECTIONS (FRI) VIA LOCAL ADMINISTRATION IN CONJUNCTION STANDARD SURGICAL CARE. FRI IS A SERIOUS, LIFE-THREATENING INFECTION WITH SIGNIFICANT ECONOMIC BURDEN. FRI TREATMENT REQUIRES HOSPITALIZATION AND ONE OR MORE REPEAT SURGICAL PROCEDURES. MICROORGANISMS THAT CAUSE FRI INCLUDE S. AUREUS, COAGULATE-NEGATIVE STAPHYLOCOCCUS SPP., ENTEROCOCCUS SPP., AND AEROBIC GRAM-NEGATIVE BACILLI. THE POTENTIAL INFECTING PATHOGEN IS UNKNOWN AT THE TIME OF TRAUMATIC INSULT AND INITIAL SURGERY. CLINICAL PRACTICE GUIDELINES RECOMMEND 2-5 DAYS OF SYSTEMIC ANTIBIOTICS FOLLOWING TRAUMATIC INJURY TO PREVENT FRI. DESPITE THIS, TRAUMATIC FRACTURES HAVE A HIGH INFECTION RATE (UP TO 40%). FRI OFTEN REQUIRES MULTIPLE SURGICAL PROCEDURES, LEADING TO SUBSTANTIAL MORBIDITY AND MORTALITY WITH AN UP TO 25% 5-YEAR MORTALITY RISK. CURRENT STRATEGIES DO NOT ADEQUATELY PREVENT THE INFECTIONS THAT LEAD T”
• PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  UEI LN53LCFJFL45

  $1.5M

  Subcontracted by this company · 2 sub-awards · latest Feb 25, 2026

  • Office of Assistant Secretary for Preparedness and Response
  • “THE MYERS LAB HAS DEVELOPED PLATFORM TECHNOLOGY FOR THE RAPID CHEMICAL SYNTHESIS OF POTENT INHIBITORS OF THE BACTERIAL LIPOPROTEIN TRANSPORT COMPLEX LOLCDE, WHICH IS SPECIFIC TO AND ESSENTIAL FOR THE GROWTH OF ENTEROBACTERIACEAE, A FAMILY OF GRAM-NEGATIVE BACTERIA. THE BREVITY OF OUR COMPONENT-BASED SYNTHETIC ROUTE, ITS NOTABLE CONVERGENCE, AND THE FACILITY WITH WHICH NEW LEAD MATTER CAN BE DISCOVERED AND SCALED ALL DIFFERENTIATE OUR PROGRAM FROM PRIOR PROGRAMS TO DISCOVER SMALL-MOLECULE INHIBITORS OF LOLCDE. THERE ARE CURRENTLY NO ANTIBIOTICS APPROVED OR IN CLINICAL DEVELOPMENT THAT TARGET LOLCDE, IN SPITE OF MUCH PRIOR EFFORT. WHAT HAS STYMIED ALL PRIOR PROGRAMS TO DEVELOP SMALL-MOLECULE INHIBITORS OF LOLCDE HAS BEEN THE OBSERVED RAPID ACQUISITION OF BACTERIAL RESISTANCE AGAINST ALL PRIOR LEAD MOLECULES, ARISING FROM SINGLE AMINO ACID MODIFICATIONS WITHIN THESE SINGLE-COPY BACTERIAL GENES (LOLC, LOLD, AND LOLE), WITH ATTENDANT MIC SHIFTS OF >16-128-FOLD VS. WILD-TYPE ENTEROBACTERIACEAE. THIS IS NOT THE CASE WITH OUR MOST POTENT INHIBITORS TO DATE. THESE LOLCDE INHIBITORS ARE WELL DIFFERENTIATED FROM ALL PRIOR SMALL-MOLECULE INHIBITORS OF LOLCDE BY THEIR OBSERVED EXTRAORDINARY POTENCIES AGAINST ENTEROBACTERIACEAE, AND, CRUCIALLY, THE FINDING THAT RESISTANCE DEVELOPMENT REQUIRES MULTIPLE CONCURRENT AMINO ACID SUBSTITUTIONS WITHIN THE LOLCDE GENE TARGETS. IT HAS BEEN SUGGESTED AND EXPERIMENTALLY SUPPORTED BY OTHERS THAT LOLCDE-TARGETING ANTIBIOTICS WILL BE LESS HARMFUL TO THE HUMAN MICROBIOTA, WHILE EFFECTIVELY ADDRESSING PATHOGENS SUCH AS E. COLI, K. PNEUMONIA, S. ENTERICA, AND OTHER ENTEROBACTERIACEAE SPP. RESISTANCE MECHANISMS WHICH PASSIVATE OTHER APPROVED GRAM-NEGATIVE ANTIBIOTICS SHOULD NOT IMPEDE OR RECOGNIZE OUR NEW LOLCDE INHIBITORS, AND PRELIMINARY EVIDENCE SUPPORTS THIS CONTENTION. THE LOCATION OF THE TARGET WITHIN THE PERIPLASMIC SPACE OF THE G-NEGATIVE PATHOGEN IS ANOTHER DIFFERENTIATION FROM EXISTING ANTIBIOTICS, WHOSE TARGETS OFTEN LIE WITHIN THE BACTE”
  • “THE MYERS LABORATORY EXTENSIVELY REDESIGNS NATURAL ANTIBIOTIC SCA¿OLDS THEN PREPARES THEM BY CHEMICAL SYNTHESIS TO ACCESS NEW ANTIBIOTICS E¿ECTIVE AGAINST MULTIDRUG-RESISTANT BACTERIAL PATHOGENS. THE STRATEGY PERMITS SCA¿OLD MODI¿CATIONS THAT CANNOT BE ACHIEVED BY SEMI- SYNTHESIS AND PROVIDES A MEANS TO OVERCOME EXISTING CLASS-BASED RESISTANCE MECHANISMS AS WELL AS BROADEN THE SPECTRUM OF ACTIVITY. RECENTLY, EXPLORATIONS TO EXPAND AND REDE¿NE THE LINCOSAMIDE CLASS HAVE DELIVERED A SET OF PARTICULARLY PROMISING LEAD MOLECULES, COLLECTIVELY TERMED THE OXEPANOPROLINAMIDES (OPPS). OPPS OVERCOME RESISTANCE MECHANISMS THAT RENDER >10 OTHER CLASSES OF RIBOSOME-TARGETING ANTIBIOTICS INACTIVE (INCLUDING LINCOSAMIDES, MACROLIDES, AND OXAZOLIDINONES) AND ARE IMPERVIOUS TO RESISTANCE MECHANISMS THAT DISABLE ANTIBIOTICS WITH DI¿ERENT TARGETS (E.G., CELL-WALL BIOSYNTHESIS INHIBITORS, AND GYRASE AND TOPOISOMERASE INHIBITORS). THE LEAD OPPS ARE POTENT, BROAD-SPECTRUM AGENTS, AND DEMONSTRATE IN VIVO E¿CACY AGAINST MULTIDRUG-RESISTANT (MDR) GRAM-POSITIVE AND GRAM-NEGATIVE ORGANISMS. OPPS SHOW EXQUISITE POTENCY IN VITRO AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, AND ENTEROCOCCUS SPP., INCLUDING STRAINS CONSTITUTIVELY EXPRESSING LINCOSAMIDE RESISTANCE DETERMINANTS. OPPS ALSO POTENTLY INHIBIT MANY HIGH-PRIORITY, MDR GRAM-NEGATIVE PATHOGENS IN VITRO INCLUDING NEISSERIA GONORRHOEAE AND ESCHERICHIA COLI. IN VITRO SAFETY PRO¿LING EXPERIMENTS REVEAL THAT OPPS SELECTIVELY INHIBIT BACTERIAL CELL GROWTH AND SUGGEST THAT THEY MAY O¿ER A LARGE THERAPEUTIC WINDOW. WITH THE SUPPORT OF CARB-X, THIS PROGRAM SEEKS TO PRO¿LE FOUR HIGHLY PROMISING LEAD MOLECULES TO ASSESS THEIR POTENTIAL AS LEAD CANDIDATES FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP). THIS PROGRAM WILL EVALUATE THE LEAD OPPS IN A WELL-DE¿NED SET OF ASSAYS TO FURTHER CHARACTERIZE THEIR SAFETY, E¿CACY, AND PHARMACOKINETIC PROPERTIES. THESE CHARACTERIZATIONS WILL ENABLE OUR GROUP TO EIT”
• DAY ZERO DIAGNOSTICS INC

  UEI KZKSJLYEAE83 · not in the directory yet

  $1.5M

  Subcontracted by this company · 1 sub-award · latest Feb 11, 2025

  • Office of Assistant Secretary for Preparedness and Response
  • “DAY ZERO DIAGNOSTICS IS DEVELOPING A CULTURE-FREE, SEQUENCING-BASED DIAGNOSTIC THAT IDENTIFIES WITHIN HOURS BOTH THE SPECIES AND THE ANTIBIOTIC RESISTANCE PROFILE OF A BACTERIAL INFECTION. WE HAVE DEVELOPED AN ULTRA-HIGH ENRICHMENT SAMPLE PREPARATION PROCESS (BLOOD2BAC‎¢) THAT CAN EXTRACT BACTERIAL WHOLE GENOME SEQUENCES FROM PATIENT BLOOD SAMPLES EVEN WHEN THERE ARE JUST A HANDFUL OF BACTERIAL CELLS PRESENT IN THE SAMPLE. WE HAVE ALSO DEVELOPED A PROPRIETARY MACHINE LEARNING ALGORITHM (KEYNOME®) THAT CAN USE THE DNA SEQUENCES TO IDENTIFY A BACTERIAL PATHOGEN AND PREDICT ITS ANTIBIOTIC SUSCEPTIBILITY PROFILE. KEYNOME IS TRAINED ON A LARGE SCALE DATABASE (MICROHMDB®) THAT CONTAINS THE WHOLE GENOME SEQUENCES OF BACTERIAL PATHOGENS MATCHED TO THEIR KNOWN ANTIBIOTIC RESISTANCE PROFILE. OUR APPROACH ALLOWS FOR THE SIMULTANEOUS TESTING OF A VAST NUMBER OF BACTERIAL SPECIES AND KNOWN RESISTANCE MARKERS, ALONG WITH THE ABILITY TO IDENTIFY NOVEL RESISTANCE DETERMINANTS AS THEY EMERGE. WITH DAY ZERO DIAGNOSTICS, PHYSICIANS CAN TREAT PATIENTS WITH THE MOST EFFECTIVE DRUG IN HOURS, AVOIDING THE COMPLICATIONS, COSTS, AND FRUSTRATION ASSOCIATED WITH EMPIRIC THERAPY.”
• MELIOLABS INC.

  UEI MEHHH8HCNVB3 · not in the directory yet

  $1.4M

  Subcontracted by this company · 1 sub-award · latest Dec 19, 2024

  • Office of Assistant Secretary for Preparedness and Response
  • “MELIO IS COMMITTED TO REVOLUTIONIZING THE HEALTHCARE INDUSTRY BY OFFERING RAPID INFECTIOUS DISEASE DIAGNOSTIC SOLUTIONS. BY REDEFINING STANDARDS OF CARE, MELIO AIMS TO DRIVE A SHIFT TOWARD PRECISION HEALTHCARE, EMPOWERING CLINICIANS TO MAKE INFORMED, TIMELY DECISIONS FOR TREATMENT FOR INFECTIONS, REDUCING HEALTHCARE COSTS, AND THE OVERPRESCRIPTION OF ANTIBIOTICS. MELIO’S FIRST PRODUCT FOCUSES ON PROVIDING A BREAKTHROUGH IN BOTH SPEED AND PATHOGEN COVERAGE FOR DIAGNOSING BLOOD STREAM INFECTIONS DIRECTLY FROM A PATIENT’S BLOOD SAMPLE FOR NEONATES. UNLIKE THE STANDARD CULTURE METHOD, WHICH SERVES AS A BOTTLENECK BY TAKING DAYS TO DELIVER RESULTS, MELIO’S TECHNOLOGY OFFERS AN EXPEDITED ALTERNATIVE THAT COULD TRANSFORM PATIENT CARE.”
• UH-OH LABS INC

  UEI SJNBW82KEKL7

  $1.3M

  Subcontracted by this company · 1 sub-award · latest Oct 22, 2025

  • Office of Assistant Secretary for Preparedness and Response
  • “THE KEY GOAL OF THIS PROGRAM IS TO DEVELOP A DESIGN-LOCKED VERSION OF STI SCOUT, AN IN VITRO DIAGNOSTIC (IVD) FOR THE DETECTION OF GONORRHEA AND CHLAMYDIA FROM MALE URINE AND FEMALE VAGINAL SWAB SAMPLES. THE TARGET PATHOGENS ARE NEISSERIA GONORRHOEAE AND CHLAMYDIA TRACHOMATIS. STI SCOUT WILL ENABLE PCR-LEVEL ACCURACY WITH THE CONVENIENCE AND COST OF RAPID ANTIGEN TESTING. COSTS OF GOODS SOLD ARE PROJECTED TO BE FAR LOWER THAN COMPETITIVE PRODUCTS, MAKING IT FINANCIALLY VIABLE TO ENTER GLOBAL LOW RESOURCE MARKETS. THE SCOUT PLATFORM INCLUDES A SCOUT HUB—A LOW-COST REUSABLE DEVICE—AND THE SCOUT CONNECT MOBILE APPLICATION FOR IOS AND ANDROID OS. TOGETHER, THESE ENABLE TESTING FOR A DEVELOPING MENU OF INDICATIONS, NOT JUST STIS, AND PERMIT RESULT TRACKING, SECURE SHARING, AND FOLLOW-ON CARE VIA TELEHEALTH. SCOUT WAS PREVIOUSLY AWARDED A CARB-X SEED AWARD CONTRACT TO DEMONSTRATE LOOP-DE-LOOP (LDL) CHEMISTRY WITH CRUDE PATIENT SAMPLES (URINE, VAGINAL SWABS). SCOUT SUCCESSFULLY COMPLETED ALL MILESTONES WITHIN THE SEED CONTRACT AND DEMONSTRATED ANALYTICAL PERFORMANCE IN POSITIVE AND PATIENT SPIKED SAMPLES THAT EXCEEDED THE TARGETS SET WITHIN THE CONTRACT. IN THIS DEVELOPMENT STAGE WORK, SCOUT WILL GENERATE ROBUST DATA AND DOCUMENTATION TO REACH DESIGN LOCK FOR STI SCOUT IN ADVANCE OF DOWNSTREAM FORMAL VERIFICATION AND VALIDATION ACTIVITIES THAT WILL EVENTUALLY SUPPORT A WHO PREQUALIFICATION AND US FDA 510(K) CLEARANCE. SCOUT WILL COMPLETE ASSAY DEVELOPMENT ACTIVITIES TO ENHANCE BOTH PERFORMANCE AND REGULATORY ALIGNMENT WITH WHO DRAFT TECHNICAL GUIDANCE. STI SCOUT PERFORMANCE AGAINST DESIGN INPUT REQUIREMENTS WILL BE ASSESSED ON THE INTEGRATED SCOUT SYSTEM (SCOUT HUB, SCOUT CONNECT APP) USING CONTROLLED TEST PROTOCOLS TO PROVIDE A SCIENTIFICALLY SOUND AND STATISTICALLY RIGOROUS EVALUATIONS. THE OUTCOME OF THIS PHASE WILL BE A CLEAR, DE-RISKED PATH TO INTERNATIONAL AND US COMMERCIALIZATION OF STI SCOUT, WITH SUPPORTING DOCUMENTATION AND EARLY PERFORMANCE AND USABILITY DATA TO”
• ARREPATH INC

  UEI U34ZFLTL1KL8

  $1M

  Subcontracted by this company · 1 sub-award · latest Mar 25, 2025

  • Office of Assistant Secretary for Preparedness and Response
  • “THE OVERALL GOAL OF THIS PROJECT IS TO DEVELOP AN IV + ORAL AGENT WITH A NOVEL MECHANISM OF ACTION (MOA) FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) CAUSED BY MDR ENTEROBACTERALES. ARREPATH HAS IDENTIFIED A SERIES OF INHIBITORS OF A HIGHLY CONSERVED ENZYME IN GRAM-NEGATIVE BACTERIA WITH NO HUMAN HOMOLOG THAT HAS NEVER BEEN CLINICALLY EXPLOITED AND IS THEREFORE CONSIDERED A NOVEL MOA. IF SUCCESSFULLY DEVELOPED, AN ANTIBIOTIC THAT INHIBITS THIS ENZYME WOULD BE ACTIVE AGAINST THE VAST MAJORITY OF ANTIBIOTIC-RESISTANT INFECTIONS CAUSED BY TARGET PATHOGENS, REPRESENTING AN IMPORTANT NEW TOOL IN THE FIGHT AGAINST ANTIMICROBIAL RESISTANCE. THE CURRENT PROPOSAL SEEKS TO OPTIMIZE PROPERTIES OF OUR INHIBITORS TO ALLOW FOR THE SELECTION OF A DEVELOPMENT CANDIDATE SUITABLE FOR IND-ENABLING STUDIES.”
• LOCUS BIOSCIENCES INC

  UEI CJKVLKZGX6F3

  $1M

  Subcontracted by this company · 1 sub-award · latest Aug 12, 2024

  • Office of Assistant Secretary for Preparedness and Response
  • “LOCUS BIOSCIENCES IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ANTIBACTERIAL THERAPIES USING ENGINEERED BACTERIOPHAGES (CRPHAGE AND DEPOLYMERASE-ENGINEERED), WHICH ARE VIRUSES THAT CAN KILL BACTERIA. THIS PROPOSAL ENABLES THE OPTIMIZATION OF AN ENGINEERED PHAGE COCKTAIL TARGETING K. PNEUMONIAE TO ADVANCE THE PRODUCT TO INITIATE A PHASE 1 CLINICAL TRIAL; A SUBSEQUENT OPTION INCLUDES EXECUTION OF THE CLINICAL TRIAL. THE PROPOSED K. PNEUMONIAE PRODUCT WILL TARGET COMPLICATED URINARY INFECTIONS. LBP-KP01 WILL BE PART OF AN ARSENAL OF COCKTAILS, INCLUDING OUR EXISTING CRPHAGE COCKTAIL TARGETING E. COLI, DESIGNED TO ADDRESS SERIOUS INFECTIONS IRRESPECTIVE OF UNDERLYING DRUG-RESISTANCE WITHIN THE TARGET SPECIES. TOGETHER, THE E. COLI AND K. PNEUMONIAE COCKTAILS HAVE THE POTENTIAL TO TREAT THE MAJORITY OF UTIS.”
• CHEMBIO DIAGNOSTIC SYSTEMS INC.

  UEI Z4B4JJDLQNK9

  $1M

  Subcontracted by this company · 1 sub-award · latest Feb 3, 2026

  • Office of Assistant Secretary for Preparedness and Response
  • “THE OBJECTIVE OF THE PROPOSED PROGRAM IS TO DEVELOP AN ACCURATE RAPID POINT-OF-CARE (POC) TEST FOR IGA ANTIBODY DETECTION IN TYPHOID FEVER USING CHEMBIO PATENTED DUAL PATH PLATFORM (DPP) TECHNOLOGY. IN THE PRESENT STAGE, WE WILL REFINE AND VERIFY THE ALPHA-PROTOTYPE DESIGN BASED ON DETECTION OF IGA ANTIBODIES TO LPS AND HLYE ANTIGENS OF SALMONELLA ENTERICA SEROVAR TYPHI. THE DPP TYPHOID IGA ASSAY WILL BE VALIDATED BY MANUFACTURING THREE DEVICE LOTS AND CONDUCTING PRE-CLINICAL EVALUATIONS AND REQUIRED ANALYTICAL STUDIES. DPP TYPHOID IGA ASSAY OFFERS SIGNIFICANT ADVANTAGES OVER THE OTHER RAPID DIAGNOSTICS AVAILABLE ON THE MARKET. IN CONTRAST TO ITS COMPETITORS TARGETING IGM AND/OR IGG ANTIBODIES, IT DETECTS IGA ANTIBODIES TO HLYE PROTEIN AND LPS, A MORE ACCURATE ANALYTE FOR RELIABLE SERODIAGNOSIS OF ACUTE INFECTION, AS DEMONSTRATED IN THREE INDEPENDENT TEST EVALUATION STUDIES PUBLISHED IN PEER-REVIEWED JOURNALS. THE DPP TYPHOID IGA ASSAY REQUIRES ONLY 10 ΜL WHOLE BLOOD, SERUM, OR PLASMA TO PRODUCE RESULTS WITHIN 15-20 MINUTES EITHER BY VISUAL READING OR BY USING AN AFFORDABLE PORTABLE ANALYZER FOR MORE OBJECTIVE TEST INTERPRETATION, HENCE FURTHER IMPROVING DIAGNOSTIC ACCURACY. THE DPP TYPHOID IGA ASSAY IS EXPECTED TO BE RELATIVELY INEXPENSIVE TO MANUFACTURE, IS SUITABLE FOR USE AT THE POINT OF CARE SETTINGS, AND REQUIRES ONLY MINIMAL TRAINING, MAKING IT AN IDEAL DIAGNOSTIC SOLUTION FOR LOW- TO MIDDLE-INCOME COUNTRIES.”
• QUANTAMATRIX INCORPORATED

  UEI V3DNM238TJM8 · not in the directory yet

  $998.1K

  Subcontracted by this company · 1 sub-award · latest Aug 18, 2025

  • Office of Assistant Secretary for Preparedness and Response
  • “QMAP (QUICK MULTIPLEXED ASSAY PLATFORM) IS A CHEAP, FAST, ACCURATE, AND HIGHLY SCALABLE FULLY AUTOMATED SYSTEM FOR NEONATAL SEPSIS SCREENING. IT CAN OFFER BROAD-SPECTRUM ANALYSIS OF MOLECULAR MARKERS REPRESENTING PATHOGEN SPECIES AND ANTIMICROBIAL RESISTANCE THROUGH A SINGLE-POT REACTION. THIS ENABLES RAPID DIAGNOSIS, PROVIDING ACCURATE RESULTS WITHIN 6 HOURS FROM LESS THAN 2 ML OF WHOLE BLOOD. THE SYSTEM EMPLOYS GRAPHICALLY ENCODED MICRODISKS, EACH ENGINEERED TO DETECT SPECIFIC ID/AST GENE MOLECULES THROUGH THE ATTACHMENT OF COMPLEMENTARY DNA PROBES, WHICH ARE SUBSEQUENTLY POOLED FOR EACH ASSAY. THE SYSTEM IS HIGHLY SCALABLE AND MULTIPLEXED, ENABLING THE INTEGRATION OF BOTH PATHOGEN ID AND AST AT A SINGLE RUN. EACH ID OR AST SPECIFIC MICRODISKS CAN BE MASS-PRODUCED AT A LOW COST. THE ONE-POT APPROACH ALLOWS PARALLEL DETECTION OF 71 GENES(ID 44 GENES AND AST 27 GENES) WITH MINIMAL USAGE OF REAGENTS AND ASSOCIATED KITS. COMPARED TO EXISTING TECHNOLOGIES, OVERALL REAGENT COSTS CAN BE REDUCED BY 4 TO 5- FOLD, WHILE ACHIEVING 2 TO 10 TIMES GREATER ID/AST GENE COVERAGE, MAKING IT IDEAL FOR A COMPREHENSIVE NEONATAL SEPSIS SCREENING PLATFORM THAT IS ALSO AFFORDABLE FOR LMICS. WITH MINIMAL SAMPLE PREPARATION AND OUR ONE-POT REACTION DESIGN, EACH STEP IS SIMPLIFIED, MINIMIZING THE RISK OF SAMPLE DILUTION OR BACTERIAL LOSS DURING TRANSFER, DISTRIBUTION, OR REACTIONS. THIS CAN POTENTIALLY REDUCE THE REQUIRED BLOOD SAMPLE VOLUME BY MORE THAN 50% COMPARED TO CONVENTIONAL DIAGNOSTICS AND ALSO ENHANCE THE SENSITIVITY OF ASSAY. FURTHERMORE, THE SYSTEM ULTIMATELY ENABLES THE DETECTION OF OVER 100 DISTINCT PROBES BY INCORPORATING ADDITIONAL TYPES OF MICRODISKS. THIS FLEXIBILITY ALLOWS QMAP TO EXPAND ITS PANEL LIBRARY TO INCLUDE NEW PATHOGENS OR AMR GENES, PROVIDING AN ADAPTABLE SOLUTION FOR EVOLVING CLINICAL REQUIREMENTS. MANY COMPANIES HAVE DEVELOPED METHODS(FLUORESCENCE-BASED PRINCIPLE, NMR-BASED PRINCIPLE, ELECTROCHEMICAL-BASED PRINCIPLE) TO MAXIMIZE THE DETECTION COVERAGE FOR COM”
• SERES THERAPEUTICS, INC.

  UEI X7LRVD7ZXMK5

  $895.7K

  Subcontracted by this company · 1 sub-award · latest Sep 15, 2025

  • Office of Assistant Secretary for Preparedness and Response
  • “SERES IS DEVELOPING A NOVEL LIVE BIOTHERAPEUTIC PRODUCT (LBP) OF HUMAN COMMENSAL BACTERIA FORMULATED FOR ORAL LIQUID DELIVERY, TO ADDRESS THE UNMET NEED FOR PREVENTION OF GUT-SEEDED AMR INFECTION IN THE MEDICAL ICU. INFECTIONS WITH PATHOGENIC (OFTEN MULTIDRUG RESISTANT, MDR) BACTERIA ARE THE LEADING CAUSE OF MORTALITY IN THE MEDICAL INTENSIVE CARE UNIT (ICU), CAUSING UP TO 9 DEATHS FOR EVERY 100 ICU PATIENTS ADMITTED (VINCENT, 2009). MOST PATIENTS ARE ADMITTED TO THE MEDICAL ICU WITH A KNOWN OR SUSPECTED INFECTION (I.E., SEPSIS) BUT, WITH TARGETED OR EMPIRIC ANTIBIOTICS, MOST RECOVER FROM THIS INITIAL INFECTION. WHAT CAUSES DEATHS—AND WHAT THIS PROJECT PROPOSES TO PREVENT—ARE THE SECONDARY, HEALTHCARE- ASSOCIATED INFECTIONS THAT FREQUENTLY DEVELOP DURING THE PROLONGED RECOVERY FROM SEPSIS. A NOVEL APPROACH THAT ADDRESSES BOTH GUT COLONIZATION AND SUBSEQUENT TRANSLOCATION BY E. COLI AND OTHER GUT SEEDED PATHOGENS COULD PREVENT A SIGNIFICANT PROPORTION OF THESE INFECTIONS. IF GUT COLONIZATION AND TRANSLOCATION BY E. COLI COULD BE AMELIORATED BY A LBP SUCH AS SER-155, A LARGE PROPORTION OF THESE INFECTIONS COULD BE PREVENTED. SER-155 IS CURRENTLY IN CLINICAL DEVELOPMENT AND HAS BEEN EVALUATED IN ALLOGENEIC HCT PATIENTS. DATA FROM OUR PHASE 1B STUDY SUPPORTS THE SAFETY AND EFFICACY OF SER-155 IN PREVENTING INFECTION IN IMMUNE COMPROMISED, HOSPITALIZED PATIENTS. THE PROPOSED WORK WILL EXTEND THESE FINDINGS BY DEVELOPING A LIQUID FORMULATION OF SER-155 (“SER-155-LF"), A NECESSARY STEP IN THE MEDICAL ICU AS PATIENTS ARE COMMONLY INTUBATED WITH NARROW-CALIBER GASTRIC OR DUODENAL FEEDING TUBES, PLACED FOR THE DELIVERY OF MEDICATIONS AND ENTERAL NUTRITION. UPON SUCCESSFUL DEVELOPMENT OF A LIQUID FORMULATION WHICH IS SUITED FOR DELIVERY IN THE ICU VIA NG TUBE, THE PROPOSED WORK PLAN WILL NEXT FOCUS ON GMP MANUFACTURING OF SER-155-LF FOR CLINICAL STUDY AND PREPARATION OF AN EARLY PHASE TRIAL IN ICU PATIENTS WITH A PRIMARY OUTCOME OF SAFETY AND ENGRAFTMENT, EXPLORATORY ENDPOINTS”
• BEA B.V.

  UEI YZ7UKLH4DHU8 · not in the directory yet

  $800K

  Subcontracted by this company · 1 sub-award · latest Apr 13, 2026

  • Office of Assistant Secretary for Preparedness and Response
  • “GONORRHEA IS A SEXUALLY TRANSMITTABLE DISEASE THAT IS CAUSED BY INFECTION WITH NEISSERIA GONORRHOEAE BACTERIA (ALSO KNOWN AS GONOCOCCI). IT AFFECTS CLOSE TO 100 MILLION PEOPLE WORLDWIDE ON A YEARLY BASIS AND ALTHOUGH MORTALITY IS LOW, THE DISEASE CAN HAVE SEVERE HEALTH CONSEQUENCES LIKE INFERTILITY, NEONATAL BLINDNESS, AND INCREASED RISK OF HIV INFECTION. ANTIBIOTIC-BASED TREATMENT IS UNDER INCREASED PRESSURE BECAUSE OF THE RISE OF MULTI DRUG RESISTANCE STRAINS AND IN SOME CASES, CLINICIANS HAVE TO RESORT TO SO-CALLED ‘LAST LINE’ ANTIBIOTICS. VACCINE DEVELOPMENT AGAINST GONOCOCCI HAS FOR DECADES BEEN HAMPERED BY THE MULTITUDE OF WAYS THAT THESE BACTERIA USE TO EVADE THE HUMAN IMMUNE SYSTEM AS WELL AS THEIR STRONG GENETIC VARIATION. CURRENTLY NO VACCINE AGAINST GONORRHEA IS AVAILABLE. EPIDEMIOLOGICAL FINDINGS SUGGEST THAT PEOPLE PREVIOUSLY VACCINATED AGAINST MENINGITIS USING OUTER MEMBRANE VESICLES (OMVS) HARVESTED FROM NEISSERIA MENINGITIDIS, A CLOSE RELATIVE OF THE GONOCOCCUS, HAVE A REDUCED RISK OF CONTRACTING GONORRHEA. FROM A BIOLOGICAL PERSPECTIVE, THIS CROSS-PROTECTION MAY BE DUE TO THE FACT NEISSERIA GONORRHOEAE AND NEISSERIA MENINGITIDIS SHARE A HIGH DEGREE OF GENETIC HOMOLOGY AND EXPRESS MANY CONSERVED OUTER MEMBRANE ANTIGENS. OMVS PRESENT THESE MEMBRANE PROTEINS IN THEIR NATIVE CONFORMATION, TOGETHER WITH INNATE IMMUNE STIMULATORY COMPONENTS, ENABLING THE INDUCTION OF CROSS-REACTIVE BACTERICIDAL ANTIBODIES. ADJANE IS DEVELOPING A VACCINE FOR GONORRHEA BASED ON ITS NEISSERIA MENINGITIDIS OMV (NM-OMV) PLATFORM TECHNOLOGY. THE NEISSERIA MENINGITIDIS BACTERIA ARE DESIGNED TO EXPRESS NEISSERIA GONORRHOEAE ANTIGENS ON THEIR SURFACE, WHERE EACH ANTIGEN PLAYS AN ESSENTIAL ROLE IN GONOCOCCAL SURVIVAL OR PATHOGENESIS, IS SURFACE-EXPOSED AND ACCESSIBLE TO FUNCTIONAL ANTIBODIES, AND IS HIGHLY CONSERVED ACROSS SEQUENCED GONOCOCCAL GENOMES, AN IMPORTANT FEATURE GIVEN THE ANTIGENIC VARIABILITY OF NEISSERIA GONORRHOEAE. IN ADDITION, THE IMMUNOGENICITY OF THE NEISSERIA GON”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.